Title: Operation APOLLO 4 6 Month Followup Interview Preliminary Findings
1Operation APOLLO4 - 6 Month Follow-up
InterviewPreliminary Findings
- Mark A. Zamorski, MD, MHSA
- Post-deployment Health Section
- Directorate of Medical PolicyCanadian Forces
2Objectives
- Become familiar with the general content and
process of the 4 to 6 month post-deployment
follow-up interview process - Understand the findings of the members
evaluations of the process
3Rationale
- Following deployment, Canadian Forces members
experience - Higher levels of stress (during and after
deployment) - Higher rates of diagnosable mental illness after
deployment, particularly mood and anxiety
disorders - Higher rates of medically unexplained physical
symptoms
4Rationale for Screening
- For depression, screening is effective
- For MUPS, it may be effective
- Screening data has epidemiological value
- 4 6 month time interval chosen
- Reintegration is more or less complete
- Stress levels stable
- Little known about this time period
5Process Overview
Member completes survey booklet (20)
Data entered into spreadsheet, generating report
(5)
Clinician reviews report (2)
Clinician interviews member (semi-structured) (30
45)
6Process Overview
Clinician makes recommendations
Member completes evaluation form
Completes Disposition Form
6 8 weeks elapse
Clinician reviews Disposition Form and
follows-up as needed
7Instruments Selected
- SF-36 health-related quality of life instrument
- Physical symptoms, mental health symptoms, and
psychosocial concerns using the PRIME-MD PHQ-15 - Post-traumatic stress phenomenology using the CF
Mississippi Short Form for Combat PTSD
8Interview Progress to Date Roto 0
3,402 deployed
3,378 home ? 4 months
554 survey data available
1,363 evaluation forms
9Sample Characteristics (N 3,402)
- 92.7 male
- Mean age 33 (SD 7)
- 10 Officer, 72 NCO
- 35 Land, 20 Air, 45 Sea
- 98 Regular Forces
- Mean deployment duration 154 days(SD 62)
10Participant Satisfaction (N1,363)
The logistics (scheduling, waiting time, etc.)
of the screening process were satisfactory
overall.
11Participant Satisfaction (N1,363)
My mental health was reviewedin appropriate
detail.
12Participant Satisfaction (N1,363)
My physical health was reviewedin appropriate
detail.
13Participant Satisfaction (N1,363)
I felt comfortable sharing personalinformation
with my interviewer.
14Participant Satisfaction (N1,363)
15Participant Satisfaction (N1,363)
By the end of the screening, my interviewer
understood my current social situation.
16Participant Satisfaction (N1,363)
My interviewer provided meuseful guidance
and/or advice.
17Participant Satisfaction (N1,363)
Overall, this post-deployment screeningprocess
was helpful to me.
18Participant Satisfaction (N1,363)
I would have liked to see a medical doctor as
part of this post-deployment screening.
19Participant Satisfaction (N1,363)
20"Do you think that some sort of post-deployment
health screening should take place in addition to
the usual medical exam that occurs immediately
after deployment?
21"Should the screening be mandatory or
optional?(for those who agreed or strongly
agreed)
22"When should the screening take place?(of those
who agreed or strongly agreedthat one should
take place)
23Exposure Concerns
I am concerned that medications, vaccinations,
chemicals, or toxins that I was exposed to in
preparation for or during my deployment may have
harmed my health.
24Participants Exposure Concerns(N 106 who
identified any)
- Anti-malarials 61
- Mefloquine 45
- Unspec. drug 12
- Primaquine 4
- Vaccines 8
- Permethrin 11
- Other agents 23
- Environ. agents 39
- Asbestos 9
- Burning waste 8
- DU 6
- Unspec. agent 6
- Dust 4
- Russian equip. 4
- Noise 2
Totals add up to more than 106 because some
respondents identified more than one exposure.
25Sample Comments(NOT Representative)
- Concerned because I don't know what I was really
exposed to and what has been actually documented - I can't say but there was probably something
there that I'll pay for in 10-20 years
26Key Findings
- 4 6 month post-deployment follow-up interview
process has been well-accepted by CF members - Perceived as thorough
- Almost all satisfied without physician visit
- 18 had exposure concerns, largely surrounding
anti-malarials
27Contact Information
- Mark A. Zamorski, MD, MHSA
- Email zamorski.ma_at_forces.gc.ca
- 1 (613) 945-8062, ext. 3507
- 1 (613) 296-3272 (mobile)